Enterprise Value Chart

Historical Enterprise Value Data

View and export this data back to 1998. Start Trial.
Date Value
November 13, 2026 2.402B
November 12, 2026 2.420B
November 11, 2026 2.412B
November 10, 2026 2.381B
November 09, 2026 2.407B
November 06, 2026 2.422B
November 05, 2026 2.407B
November 04, 2026 2.563B
November 03, 2026 2.648B
November 02, 2026 2.564B
October 30, 2026 2.622B
October 29, 2026 2.635B
October 28, 2026 2.596B
October 27, 2026 2.527B
October 26, 2026 2.471B
October 23, 2026 2.412B
October 22, 2026 2.445B
October 21, 2026 2.438B
October 20, 2026 2.486B
October 19, 2026 2.520B
October 16, 2026 2.448B
October 15, 2026 2.507B
October 14, 2026 2.514B
October 13, 2026 2.520B
October 12, 2026 2.594B
Date Value
October 09, 2026 2.642B
October 08, 2026 2.576B
October 07, 2026 2.604B
October 06, 2026 2.489B
October 05, 2026 2.527B
October 02, 2026 2.545B
October 01, 2026 2.532B
September 30, 2026 2.586B
September 29, 2026 2.595B
September 28, 2026 2.646B
September 25, 2026 2.676B
September 24, 2026 2.658B
September 23, 2026 2.671B
September 22, 2026 2.725B
September 21, 2026 2.720B
September 18, 2026 2.699B
September 17, 2026 2.704B
September 16, 2026 2.635B
September 15, 2026 2.567B
September 14, 2026 2.584B
September 11, 2026 2.556B
September 10, 2026 2.600B
September 09, 2026 2.731B
September 08, 2026 2.798B
September 04, 2026 3.026B

Enterprise Value Definition

EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.

Read full definition.

Enterprise Value Range, Past 5 Years

View Enterprise Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Enterprise Value Benchmarks

View Enterprise Value Benchmarks
Start Trial
Halozyme Therapeutics, Inc. 13.60B
Neurocrine Biosciences, Inc. 16.61B
Agenus, Inc. 487.93M
Amgen, Inc. 292.70B
Anika Therapeutics, Inc. 160.67M